Objective To compare the efficacy of covid-19 vaccines between immunocompromised and
immunocompetent people. Design Systematic review and meta-analysis. Data sources …

The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

Background: Patients with chronic inflammatory disease (CID) treated with
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …

Objectives To describe the safety of vaccines against SARS-CoV-2 in people with
inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods …

Objective There is an urgent need to assess the impact of immunosuppressive therapies on
the immunogenicity and efficacy of SARS-CoV-2 vaccination. Methods Serological and T …

The first EULAR provisional recommendations on the management of rheumatic and
musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome …

Background We describe the early experiences of adults with systemic rheumatic disease
who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted …

Objectives To better understand the factors that influence the humoral immune response to
vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases …

The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

To date, four vaccines have been authorised for emergency use and under conditional
approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 …